Strategy Inc.'s Variable Rate Series A Perpetual Stretch Preferred Stock (STRC) fell to an all-time low of $89 on June 17, 2026, trading about 11% below its $100 par value. This preferred stock, designed to fund Bitcoin purchases and pay variable dividends, now offers a yield near 12.9%, reflecting increased risk perception. The price drop paused the company's at-the-market offering program, raising concerns about a potential 'death spiral' where higher dividends to attract investors could strain cash and force asset sales. Strategy counters these worries by highlighting its liquidity, recent Bitcoin sales to cover dividends, and ongoing Bitcoin acquisitions funded by common stock sales. Market watchers will closely monitor if STRC stabilizes or requires dividend adjustments amid Bitcoin price volatility and investor sentiment shifts.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
